Analysts Offer Predictions for Verastem FY2025 Earnings

Verastem, Inc. (NASDAQ:VSTM) – Research analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Verastem in a research note issued to investors on Wednesday, February 4th. HC Wainwright analyst A. Maldonado anticipates that the biopharmaceutical company will post earnings per share of ($3.21) for the year. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Verastem’s Q4 2025 earnings at ($0.52) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($0.44) EPS, FY2028 earnings at $0.29 EPS and FY2029 earnings at $0.89 EPS.

Verastem (NASDAQ:VSTM) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.84). The business had revenue of $11.24 million during the quarter, compared to analysts’ expectations of $5.76 million.

A number of other research firms have also commented on VSTM. Royal Bank Of Canada set a $13.00 price target on shares of Verastem and gave the stock an “outperform” rating in a research report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Verastem in a report on Wednesday, January 21st. Wall Street Zen downgraded shares of Verastem from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Mizuho set a $15.00 price target on Verastem in a research note on Wednesday, October 29th. Finally, Guggenheim restated a “buy” rating on shares of Verastem in a research note on Tuesday, December 30th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.83.

Verastem Stock Down 7.5%

VSTM opened at $6.28 on Friday. The stock has a fifty day moving average of $7.83 and a 200-day moving average of $8.25. The company has a market capitalization of $419.38 million, a P/E ratio of -1.56 and a beta of 0.41. Verastem has a fifty-two week low of $4.01 and a fifty-two week high of $11.24. The company has a debt-to-equity ratio of 2.06, a quick ratio of 2.55 and a current ratio of 2.58.

Insider Activity

In other Verastem news, CFO Daniel Calkins sold 5,039 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $7.16, for a total transaction of $36,079.24. Following the completion of the transaction, the chief financial officer directly owned 104,719 shares in the company, valued at $749,788.04. The trade was a 4.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Paul A. Bunn sold 6,250 shares of the company’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $10.00, for a total value of $62,500.00. Following the sale, the director owned 2,083 shares of the company’s stock, valued at $20,830. The trade was a 75.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 50,478 shares of company stock valued at $462,045. 2.10% of the stock is owned by insiders.

Institutional Trading of Verastem

Several large investors have recently bought and sold shares of VSTM. UBS Group AG raised its stake in Verastem by 76.3% during the fourth quarter. UBS Group AG now owns 501,471 shares of the biopharmaceutical company’s stock worth $3,871,000 after acquiring an additional 217,069 shares in the last quarter. Torray Investment Partners LLC bought a new stake in shares of Verastem during the 4th quarter valued at approximately $1,671,000. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Verastem during the 4th quarter valued at approximately $1,346,000. SG Americas Securities LLC increased its position in Verastem by 3,333.8% during the 4th quarter. SG Americas Securities LLC now owns 390,325 shares of the biopharmaceutical company’s stock worth $3,013,000 after purchasing an additional 378,958 shares in the last quarter. Finally, Woodline Partners LP bought a new position in Verastem in the 3rd quarter valued at approximately $2,716,000. 88.37% of the stock is owned by institutional investors and hedge funds.

Verastem News Summary

Here are the key news stories impacting Verastem this week:

• Positive Sentiment: Company-issued preliminary Q4 and full‑year 2025 revenue and business update highlighted the commercial launch of AVMAPKI FAKZYNJA and an extended cash runway — a clear operational milestone that supports commercialization upside and reduces short-term financing risk. BusinessWire: Preliminary Q4 & 2025 Revenue & Updates
• Positive Sentiment: Market coverage notes: HC Wainwright initiated/issued detailed multi‑year EPS models and maintained a Buy rating with an $18 price target (large upside vs. current levels). The note includes upward tweaks to FY2028–FY2029 and a bullish FY2030 view, providing an analyst-driven rationale for buying interest. (Coverage reported across financial press.) Benzinga: HC Wainwright Coverage
• Positive Sentiment: Near‑term market reaction: publications reported an almost 8% intraday rise after the preliminary results, indicating investor enthusiasm around the revenue print and commercial update. Zacks: Stock Rises Nearly 8%
• Neutral Sentiment: Distribution of HC Wainwright’s detailed quarterly and annual EPS forecasts (FY2025–FY2030) suggests a long runway to profitability per the analyst model, but near‑term EPS remain negative — so upside depends on execution against commercialization and R&D milestones.
• Negative Sentiment: Insider activity: CEO Dan Paterson sold 970 shares at about $6.69 (disclosed filing). The sale is small relative to his overall holdings but can be viewed by some investors as a minor negative signal. SEC Filing: Insider Sale

About Verastem

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.